Bio-Rad Laboratories Stock
Bio-Rad Laboratories, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Norman D. Schwartz
- Employees
- 7,450
- Market cap
- $9.5 B
- IPO
- 27/02/1980
Bio-Rad Laboratories, Inc., headquartered in Hercules, USA, is a global healthcare company that went public on the NYSE on February 27, 1980. The company operates through two primary divisions, namely the Life Science segment and the Clinical Diagnostics segment. Within the Life Science division, the company develops,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Bio-Rad Laboratories stock: price history
1D
-3.0%
1W
-3.4%
1M
-6.7%
6M
+18.3%
YTD
+16.7%
1Y
+13.2%
2Y
+7.3%
5Y
-51.0%
10Y
+117.9%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~77% stronger price swings than usual
Bio-Rad Laboratories stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Very robust business model with strong megatrend tailwind: wide moat, strong pricing power, predictable revenue.
1 more assignment (Enabler/Second row) Pro-only.
Bio-Rad Laboratories is a globally operating provider in the field of bioscience research and clinical diagnostics. The company divides its business activities into two main segments: Life Science and Clinical Diagnostics. In the Life Science segment, the company develops and distributes reagents, laboratory instruments, and equipment for research, biopharmaceutical production, and food safety. The Clinical Diagnostics segment focuses on specialized niches in the in vitro diagnostics market through test systems, diagnostic kits, and software solutions for clinical laboratories. Products are delivered through an international distribution network comprising both direct sales personnel and third-party providers such as distributors and resellers.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Bio-Rad Laboratories
Analyst assessment of Bio-Rad Laboratories
PRICE TARGET LOW
US$310.00
CONSENSUS
US$350.00
MEDIAN
US$350.00
PRICE TARGET HIGH
US$390.00
1
STRONG BUY
7
BUY
6
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 07/08/2026
Bio-Rad Laboratories stock metrics
P/E
42.46
P/B
1.32
EV/EBITDA
19.72
RETURN ON EQUITY
5.2%
NET MARGIN
57.1%
DEBT/EQUITY
0.17
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
66.7%
FLOAT SHARES
17,840,145
AVG. DAILY VOLUME (30D)
255,531
Insider transactions (SEC)
Mehta Rajat
ENLOE COURTNEY C
ENLOE COURTNEY C
BARRY JAMES
BARRY JAMES
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -3.0%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Bio-Rad Laboratories stock
What does Bio-Rad Laboratories do?
Bio-Rad Laboratories, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Norman D. Schwartz, the company employs around 7,450 people.
The IPO was on 27/02/1980; the stock trades on NYSE under the ticker BIO.
What do analysts say about Bio-Rad Laboratories stock?
14 analysts rate the stock, the consensus is Buy (as of 07/08/2026).
The average price target is US$350.00, ranging from US$310.00 to US$390.00, with a median of US$350.00.
This is an external assessment, not a statement by Market Jury.
When does Bio-Rad Laboratories report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 77% stronger than usual.
Does Bio-Rad Laboratories pay a dividend?
No, Bio-Rad Laboratories currently does not pay a dividend.
Which stocks are comparable to Bio-Rad Laboratories?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Bio-Rad Laboratories stock analyzed?
Clicking "Analyze stock" lets five strategies assess Bio-Rad Laboratories against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.